6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03149809 (ClinicalTrials.gov)	March 1, 2018	9/5/2017	Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease	Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease	Overactive Bladder;Parkinson Disease	Drug: solifenacin;Behavioral: Pelvic floor muscle exercise-based behavioral therapy	VA Office of Research and Development	NULL	Recruiting	N/A	N/A	All	90	Phase 3	United States
2	NCT01018264 (ClinicalTrials.gov)	January 2010	19/11/2009	Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease	URGE-PD: A Multi-site, Double-blind, Randomized, Placebo Controlled Trial of Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease	Overactive Bladder in Parkinson's Disease	Drug: solifenacin succinate (VESIcare);Drug: placebo	University of South Florida	NULL	Completed	40 Years	80 Years	All	23	Phase 4	United States
3	NCT00584090 (ClinicalTrials.gov)	November 2007	21/12/2007	Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease		Urinary Incontinence;Parkinson's Disease	Drug: Solifenacin Succinate (VESIcare);Drug: Placebo	University of South Florida	NULL	Withdrawn	30 Years	80 Years	Both	0	Phase 4	United States